Thursday, 24 December 2015

Biocon rallies 5.3% on launches CIMIVIR-L for Hepatitis-C

The company has introduced the an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis-C in India.


Biocon Limited
Biocon rallied 5.7% to Rs.509 after the company has introduced the an advanced novel therapy CIMIVIR-L for the treatment of Hepatitis-C in India.

The scrip opened at Rs. 485.05 and has touched a high and low of Rs. 509.65 and Rs. 484 respectively. So far 596886(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 9635 crore.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 495.7 on 15-Apr-2015 and a 52 week low of Rs. 396.5 on 25-Aug-2015. Last one week high and low of the scrip stood at Rs. 487.25 and Rs. 470.25 respectively.

The promoters holding in the company stood at 61.02 % while Institutions and Non-Institutions held 19.21 % and 19.76 % respectively.

The stock is currently trading below its 50 DMA.

No comments:

Post a Comment